Coffee Consumption After Laparoscopic Hysterectomy (COFFEE-LH)

July 6, 2026 updated by: muzeyyen ataseven, Istanbul Medipol University Hospital

Effect of Postoperative Coffee Consumption on Bowel Motility and Length of Hospital Stay Following Laparoscopic Hysterectomy: A Randomized Controlled Trial

Postoperative ileus and delayed bowel recovery remain common concerns following laparoscopic hysterectomy despite enhanced recovery protocols. Coffee consumption has been suggested as a simple, safe, and inexpensive intervention that may stimulate gastrointestinal motility and accelerate postoperative recovery. This randomized controlled trial aims to evaluate the effect of postoperative coffee consumption on bowel function recovery and length of hospital stay in women undergoing laparoscopic hysterectomy. Eligible participants are randomly assigned to either a coffee intervention group receiving standard postoperative care plus coffee at predetermined postoperative time points or a control group receiving standard postoperative care alone. The primary objective is to determine whether postoperative coffee consumption improves bowel recovery and shortens hospitalization.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Laparoscopic hysterectomy is one of the most commonly performed minimally invasive gynecological procedures. Although enhanced recovery after surgery (ERAS) protocols have improved postoperative outcomes, delayed gastrointestinal recovery and postoperative ileus continue to affect patient recovery, comfort, and hospital length of stay.

Coffee contains several bioactive compounds that may stimulate gastrointestinal motility through multiple physiological mechanisms, including increased gastrin secretion, activation of the gastrocolic reflex, and enhanced colonic motor activity. Previous clinical studies have suggested that postoperative coffee consumption may accelerate bowel function recovery after abdominal surgery; however, evidence specific to laparoscopic hysterectomy remains limited.

This single-center, randomized controlled trial evaluates the effectiveness of postoperative coffee consumption in women undergoing laparoscopic hysterectomy. Fifty eligible participants are randomly allocated in a 1:1 ratio to either an intervention group or a control group using block randomization. Participants in the intervention group receive standard postoperative care together with 100 mL of soluble coffee prepared with hot water at postoperative hours 6, 12, and 18, whereas participants in the control group receive standard postoperative care alone.

The study evaluates postoperative bowel recovery by assessing bowel sounds, passage of flatus, passage of stool, abdominal distension, nausea, vomiting, distension-related pain, and length of hospital stay. The findings are expected to provide evidence regarding a simple, low-cost, and feasible nursing intervention that may improve postoperative recovery following laparoscopic hysterectomy.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34810
        • Istanbul Bağcılar Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Women aged 18 years or older.
  • Scheduled for elective laparoscopic hysterectomy.
  • Able to consume oral fluids according to the ERAS protocol.
  • Able to communicate in Turkish.
  • Willing to participate and provide written informed consent.

Exclusion Criteria:

  • Emergency surgery.
  • Known allergy or intolerance to coffee or caffeine.
  • Gastrointestinal diseases or conditions affecting bowel motility.
  • Postoperative complications requiring intensive care or preventing oral intake.
  • Withdrawal of informed consent at any stage of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Coffee Group
Participants received standard postoperative care plus 100 mL of soluble coffee prepared with hot water at postoperative 6, 12, and 18 hours.
Behavioral: Postoperative Coffee Consumption
Participants received 100 mL of hot soluble coffee prepared with hot water at postoperative hours 6, 12, and 18 in addition to standard postoperative ERAS care.
No Intervention: Control Group
Participants received standard postoperative care according to institutional clinical practice without postoperative coffee consumption.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Passage of Flatus
Time Frame: From the end of surgery until the first passage of flatus, assessed for up to 72 hours after surgery.
Time from the end of surgery to the first passage of flatus, recorded in hours.
From the end of surgery until the first passage of flatus, assessed for up to 72 hours after surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to First Defecation
Time Frame: From the end of surgery until the first bowel movement, assessed for up to 72 hours after surgery.
Time from the end of surgery to the first bowel movement.
From the end of surgery until the first bowel movement, assessed for up to 72 hours after surgery.
Time to First Bowel Sounds
Time Frame: From the end of surgery until the first bowel sounds are detected, assessed for up to 72 hours after surgery.
Time from the end of surgery to the first audible bowel sounds.
From the end of surgery until the first bowel sounds are detected, assessed for up to 72 hours after surgery.
Length of Hospital Stay
Time Frame: From the date of surgery until hospital discharge, assessed for up to 5 days after surgery.
Duration of hospitalization from surgery until discharge.
From the date of surgery until hospital discharge, assessed for up to 5 days after surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Medipol University Hospital

Collaborators

Bagcilar Training and Research Hospital

Investigators

  • Principal Investigator: Müzeyyen Ataseven, PhD,RN, Istanbul Medipol University, Faculty of Health Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2025

Primary Completion (Actual)

October 25, 2025

Study Completion (Actual)

October 25, 2025

Study Registration Dates

First Submitted

June 29, 2026

First Submitted That Met QC Criteria

July 6, 2026

First Posted (Actual)

July 7, 2026

Study Record Updates

Last Update Posted (Actual)

July 7, 2026

Last Update Submitted That Met QC Criteria

July 6, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • LHCOFFEE2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared. The study did not include a data-sharing plan, and participant confidentiality will be maintained.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hysterectomy

Clinical Trials on Postoperative Coffee Consumption

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe